Beyond the Mainstream: Tiangong’s PCB Pivot and Viva Biotech’s AI PushGlobal Report·Aug 18 at 04:43 AM08549+0.48%09993+0.42%
VIVA Biotech schedules board meeting to review interim results, consider dividendPUBT·Aug 14 at 03:31 AM01873+0.63%
Hong Kong Equities Diverge as Infrastructure Expands and Healthcare Faces Governance TestsGlobal Report·Aug 11 at 05:13 AM01164+9.19%01199+1.83%
AI Infrastructure Buildout and Biomedical Pivots Dictate Hong Kong Mid-Cap VolatilityGlobal Report·Aug 11 at 05:12 AM06682-5.11%01698-1.76%
Hong Kong Mid-Caps on the Move: Key Tech and Biotech UpdatesGlobal Report·Aug 5 at 04:13 AM01530+8.06%02669+7.58%
Hong Kong Equities See Reshuffling Amid Buybacks and Asset SalesGlobal Report·Jul 28 at 04:12 AM01873+0.63%02656+1.63%
VIVA Biotech files HKEX next-day disclosure return, reports share repurchase for cancellationPUBT·Jun 26 at 06:22 AM01873+0.63%
VIVA Biotech shareholders adopt 2025 audited financial statements at AGMPUBT·Jun 26 at 03:31 AM01873+0.63%
Viva Biotech grants 6.22 million RSUs to CDMO staff at HK$ 1.08 eachPUBT·Jun 26 at 02:23 AM01873+0.63%
KE Holdings files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jun 24 at 06:37 AMBEKE-2.24%02423+2.86%
Viva Biotech files HKEX next-day disclosure return announcing share repurchase for cancellation at HKD 1.12 eachPUBT·Jun 24 at 05:06 AM01873+0.63%
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug DiscoveryPR Newswire·May 27 at 09:37 PM01873+0.63%FBT-1.38%
05:19 ETFifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturingprnewswire·Apr 7 at 04:20 AM01873+0.63%FBT-1.38%
10:01 ETViva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Upprnewswire·Mar 30 at 09:03 AM01873+0.63%FBT-1.38%
